Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03859700 · ClinicalTrials.gov registry record · Phase 3
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
A Phase 3 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
NCT03859700 is a Phase 3 study that has completed, run by DBV Technologies. The registered enrollment target is 304 participants.
The verdict
NCT03859700, a Phase 3 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
Study Summary
Open-label, follow-up study for subjects who completed the EPITOPE study.
Interventions
- BIOLOGICAL DBV712 250 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2025-05-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03859700
The ClinicalTrials.gov registry entry for NCT03859700 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DBV712 250 mcg is the first listed.
NCT03859700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03859700 about?
NCT03859700 is a clinical study titled "Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children". Open-label, follow-up study for subjects who completed the EPITOPE study.
What is the current status of trial NCT03859700?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2018-12-06. Estimated completion is 2025-05-13.
What interventions are being tested in trial NCT03859700?
The interventions under investigation include: DBV712 250 mcg (BIOLOGICAL).
Who is sponsoring clinical trial NCT03859700?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.